• Record sales orders of $63.4 million (+22% YoY)
• Revenue of $51.0 million (+2% YoY), with strong performance in sleep diagnostics and SaaS
• EBITDA of $2.9 million (+9% YoY)

FY25 marked a pivotal year for Compumedics, with the business delivering record sales orders of $63.4 million (+22% YoY) and revenue of $51.0 million (+2% YoY). The company made strong progress on its strategy to scale recurring revenue, expand global commercial reach, and advance new product platforms. Key highlights include: Sleep Diagnostics - Capital Equipment revenue increased 39% YoY to $18.2 million, reflecting strong demand across international markets, particularly in the U.S. and Asia. Sleep - SaaS (Somfit + Nexus 360) revenue grew 40% YoY to $6.0 million, underpinned by accelerating adoption. Neurology - Capital Equipment revenue was flat at $14.3 million, with growth in the Okti wireless EEG system and Neuroscan solutions supporting adoption. Service & Supplies - Recurring revenue reached $7.8 million, enhancing customer lifetime value and margin stability. DWL - Blood Flow Diagnostics Capital Equipment revenue recovered to $4.7 million. No MEG revenue was recognized in FY25, but three new MEG system orders totalling over $15 million were secured for delivery in FY26. Geographically, the U.S. grew 118% YoY to $20.9 million, while Asia Pacific continued to be a high-growth region. Compumedics reported FY25 EBITDA of $2.9 million, up 9% YoY, reflecting disciplined execution across commercial, operational, and product segments.